| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
257.67(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
180,030 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,509,387 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
9 |
21 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Grooms Jamie Mark |
Director |
– • – |
2017-12-07 |
4 |
S |
$26.50 |
$826,800 |
D/D |
(31,200) |
313,117 |
|
- |
|
| Grooms Jamie Mark |
Director |
– • – |
2017-12-06 |
4/A |
AS |
$26.22 |
$558,224 |
D/D |
(21,290) |
344,317 |
|
- |
|
| Grooms Jamie Mark |
Director |
– • – |
2017-12-06 |
4 |
S |
$26.22 |
$558,224 |
D/D |
(21,290) |
344,317 |
|
- |
|
| Neels Guido J |
Director |
– • – |
2017-11-20 |
4 |
S |
$19.74 |
$22,701,000 |
I/I |
(1,150,000) |
3,371,111 |
|
- |
|
| Essex Woodlands Fund Ix, L.p. |
10% Owner |
– – • |
2017-11-20 |
4 |
S |
$19.74 |
$22,701,000 |
D/D |
(1,150,000) |
3,711,111 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2017-11-13 |
4 |
OE |
$5.09 |
$76,350 |
D/D |
15,000 |
360,248 |
|
- |
|
| Grooms Jamie Mark |
Director |
– • – |
2017-11-01 |
4 |
D |
$20.60 |
$3,893 |
D/D |
(189) |
365,607 |
|
- |
|
| Grooms Jamie Mark |
Director |
– • – |
2017-11-01 |
4 |
OE |
$0.27 |
$3,882 |
D/D |
14,379 |
365,796 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2017-10-24 |
4 |
OE |
$1.07 |
$174,962 |
D/D |
67,767 |
67,952 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2017-10-24 |
4 |
D |
$20.00 |
$109,600 |
D/D |
(5,480) |
40,185 |
|
- |
|
| Freitag Gregory Gene |
General Counsel & SVP BD |
• • – |
2017-09-25 |
4 |
D |
$18.90 |
$27,405 |
D/D |
(1,450) |
99,666 |
|
- |
|
| Freitag Gregory Gene |
General Counsel & SVP BD |
• • – |
2017-09-25 |
4 |
OE |
$2.74 |
$27,400 |
D/D |
10,000 |
101,116 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2017-09-11 |
4 |
AS |
$18.00 |
$290,574 |
D/D |
(16,143) |
23,273 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2017-09-08 |
4 |
D |
$18.15 |
$70,005 |
D/D |
(3,857) |
39,416 |
|
- |
|
| Rudelius Robert James |
Director |
– • – |
2017-09-08 |
4 |
OE |
$3.50 |
$70,000 |
D/D |
20,000 |
43,273 |
|
- |
|
| Freitag Gregory Gene |
General Counsel & SVP BD |
• • – |
2017-08-27 |
4 |
D |
$16.65 |
$63,020 |
D/D |
(3,785) |
91,116 |
|
- |
|
| Freitag Gregory Gene |
General Counsel & SVP BD |
• • – |
2017-08-27 |
4 |
OE |
$2.74 |
$63,020 |
D/D |
23,000 |
94,901 |
|
- |
|
| Mccarrey Shawn F |
SVP Sales |
• – – |
2017-08-02 |
4 |
D |
$15.15 |
$36,102 |
D/D |
(2,383) |
39,167 |
|
- |
|
| Mccarrey Shawn F |
SVP Sales |
• – – |
2017-08-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,150 |
41,550 |
|
- |
|
| Gingrich Jon S. |
Chief Commercial OfficerOffice |
• – – |
2017-07-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
650 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2017-05-30 |
4 |
OE |
$8.95 |
$44,750 |
D/D |
5,000 |
345,248 |
|
- |
|
| Gold Mark Stephen |
Director |
– • – |
2017-05-22 |
4 |
OE |
$4.81 |
$72,150 |
D/D |
15,000 |
340,248 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2017-03-14 |
4 |
OE |
$0.27 |
$14,958 |
D/D |
9,659 |
9,659 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2017-03-14 |
4 |
OE |
$0.27 |
$1,355 |
D/D |
5,018 |
5,018 |
|
- |
|
| Freitag Gregory Gene |
General Counsel & SVP BD |
• • – |
2016-12-30 |
4 |
OE |
$2.74 |
$63,020 |
D/D |
23,000 |
71,901 |
|
- |
|
529 Records found
|
|
Page 17 of 22 |
|
|
0.11 (1.81%) 
